Traws Pharma Faces Delisting Concerns
Ticker: TRAW · Form: 8-K · Filed: Nov 22, 2024 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $2.5 million, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Traws Pharma might get delisted, big trouble ahead.
AI Summary
Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on November 22, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company's principal executive offices are located at 12 Penns Trail, Newtown, PA.
Why It Matters
This filing indicates potential issues with Traws Pharma's continued listing on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a severe risk to investors.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former company name
- November 20, 2024 (date) — Date of earliest event reported
- November 22, 2024 (date) — Filing date
- 12 Penns Trail, Newtown, PA (location) — Business address
FAQ
What specific listing rule or standard has Traws Pharma, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Traws Pharma, Inc. has failed to satisfy, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 20, 2024.
What was Traws Pharma, Inc. previously known as?
Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc.
What is the business address of Traws Pharma, Inc.?
The business address of Traws Pharma, Inc. is 12 Penns Trail, Newtown, PA.
What is the SEC file number for Traws Pharma, Inc.?
The SEC file number for Traws Pharma, Inc. is 001-36020.
Filing Stats: 634 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2024-11-22 17:00:30
Key Financial Figures
- $2.5 million — o longer in compliance with the minimum $2.5 million stockholders' equity requirement for co
- $1.00 — th the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 581
Filing Documents
- tm2429248d1_8k.htm (8-K) — 24KB
- 0001104659-24-122149.txt ( ) — 192KB
- tmb-20241120.xsd (EX-101.SCH) — 3KB
- tmb-20241120_lab.xml (EX-101.LAB) — 33KB
- tmb-20241120_pre.xml (EX-101.PRE) — 22KB
- tm2429248d1_8k_htm.xml (XML) — 4KB
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2024, the Company received a letter from the Nasdaq Staff (the "Staff") stating that the Company was no longer in compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"), and that the Staff had determined that this issue is an additional basis to delist the Company's securities from The Nasdaq Capital Market. The Company has presented its plan of compliance before the Nasdaq Hearings Panel (the "Nasdaq Panel") at a hearing held on November 14, 2024. As previously disclosed, on September 24, 2024, the Company received a letter from the Staff stating that the Company had not been able to regain compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5810(c)(3)(A) (the "Bid Rule"), and that the Staff had determined to delist the Company's securities from Nasdaq unless the Company requested a hearing before the Nasdaq Panel by October 1, 2024. Therefore, the Company requested a hearing. On October 29, 2024, the Company was notified by Staff that it had regained compliance with the Bid Price Rule because the Company's common stock had a minimum closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. While this action would have normally resulted in the Company being out of the hearings process by the Nasdaq Panel, the Company recognized and self-reported that it would be non-compliant with the Equity Rule upon filing its upcoming Form 10-Q on November 14, 2024. Therefore, the Company proactively requested that the Hearings Panel keep the hearings date scheduled on November 14, 2024 and that it address solely the Equity Rule. The Company is currently waiting on the Nasdaq Panel's determination with regard to the Equity Rule. 1 SIGNATURE Pu